All In Biotech

Drug Trial Radar · NCT05377580

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI112 in Patients With Moderate to Severe Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Jul 1, 2022

Primary completion

Jun 21, 2024

Study completion Aug 7, 2025

Sponsor

Sponsor type
Industry
First posted
May 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of IBI112 induction therapy in patients with moderate and severe active Ulcerative Colitis (UC) to achieve clinical remission.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • Period 1 IBI112 PlaceboDrug

    Intravenous Injection

  • Period 2 IBI112 dose 3Drug

    Subcutaneous injections

  • Period 1 IBI112 dose 1Drug

    Intravenous Injection

  • Period 1 IBI112 dose 2Drug

    Intravenous Injection

  • Period 2 IBI112 dose 4Drug

    Intravenous Injection

  • Period 2 IBI112 PlaceboDrug

    Subcutaneous injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the effectiveness of IBI112 in inducing clinical remission in patients with moderately to severely active ulcerative colitis (UC)Time frame: week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.